Boothbay Fund Management’s NewAmsterdam Pharma NAMS Stock Holding History

Boothbay Fund Management’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.21M	Buy	35,756 +8,420	+31%	+$277K	0.02%	986
2026 Q1	$875K	Sell	27,336 -6,583	-19%	-$214K	0.01%	1015
2025 Q4	$1.19M	Sell	33,919 -6,795	-17%	-$247K	0.02%	735
2025 Q3	$1.16M	Sell	40,714 -19,340	-32%	-$464K	0.02%	773
2025 Q2	$1.09M	Sell	60,054 -68,821	-53%	-$1.26M	0.02%	663
2025 Q1	$2.64M	Buy	128,875 +93,308	+262%	+$2.07M	0.07%	369
2024 Q4	$914K	Buy	+35,567	New	+$755K	0.02%	675

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Boothbay Fund Management's NAMS Position: Q2 2026 in Review

Boothbay Fund Management increased its NewAmsterdam Pharma (NAMS) stake by 31% in Q2 2026, buying an estimated $277K and bringing the position to 35,756 shares worth $1.21M. The position accounts for 0.02% of the portfolio, ranked #986.

Boothbay Fund Management first reported a position in NAMS in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.64M in Q1 2025. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Boothbay Fund Management held 35,756 shares of NewAmsterdam Pharma worth $1.21M as of Q2 2026.
Boothbay Fund Management bought 8,420 NewAmsterdam Pharma shares in Q2 2026, an estimated $277K.
NewAmsterdam Pharma made up 0.02% of Boothbay Fund Management's portfolio in Q2 2026, its #986 holding.
Boothbay Fund Management first reported a position in NewAmsterdam Pharma in Q4 2024 and has held it in 7 quarters since.
Boothbay Fund Management's NewAmsterdam Pharma position peaked at $2.64M in Q1 2025.
194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.